Thermo Fisher Scientific Inc.

Named one of the world's most innovative companies by Clarivate Analytics for three consecutive years

World's Most Innovative Companies

Collaboration to accelerate AI development in healthcare, integrating NVIDIA's technologies into Medtronic's GI Genius™ intelligent endoscopy module.

AI Development in Healthcare

Global pilot program using AI technology to enhance aortic patient treatment decisions across 40 sites.

AI-Enhanced Aortic Treatment

Strategic partnership for co-promotion of CathWorks' FFRangio® System for coronary artery disease diagnosis and treatment.

Coronary Artery Disease Diagnosis

Global partnership to expand CGM options for people with diabetes, collaborating on an integrated CGM based on Abbott's advanced platform.

Continuous Glucose Monitoring

Partnership for exclusive U.S. distribution rights of the BioButton® wearable for continuous patient monitoring.

Continuous Patient Monitoring

Global partnership to explore opportunities in advanced pre- and post-operative imaging technologies for spine care.

Advanced Imaging for Spine Care

A new configurable one-system ECMO solution launched in September 2024

VitalFlow™ ECMO System

An innovative system integrating navigation, robotics, data, AI, imaging, software, and implants for spine and cranial procedures

AiBLE™ spine surgery ecosystem

Platform launched in October 2022 to accelerate innovation in stroke treatment

Medtronic Neurovascular Co-Lab™ Platform

Transcatheter aortic valve replacement system showing superior valve performance compared to surgery in randomized trials

Evolut FX TAVR system

The first FDA-approved pulsed field ablation system for cardiac ablation

PulseSelect PFA system

Development of AI-powered intelligent endoscopy system for early detection of colorectal cancer

Cancer screening using AI and machine learning

Ongoing development of advanced diabetes management technologies

Diabetes management technologies

Initiatives through Medtronic LABS to increase healthcare accessibility

Expanding healthcare access in underserved communities

Medtronic, a global healthcare technology company specializing in medical devices and therapies, invested $2.74 billion in R&D and held 202 active patent families in 2023. Its technologies address over 70 health conditions, integrating AI, data analytics, and robotics into healthcare. Medtronic's innovation strategy includes an AI Center of Excellence, an Innovation Lab, and strategic partnerships. Medtronic LABS' SPICE, an open-source digital platform, uses machine learning to improve healthcare delivery in underserved communities.

Dedicated center for leveraging artificial intelligence platforms across Medtronic's product portfolio

AI Center of Excellence

A dedicated center focused on integrating artificial intelligence and machine learning into Medtronic's medical devices and therapies.

Medtronic AI Center of Excellence

Significant internal funding dedicated to research and development activities

Internal R&D Investment

Medtronic

Geoff Martha

Fortune 500 company

S&P 100 component

Recognized for significant increase in patent activity

Q2 2024 highest growth in patent filings and grants

Three awards for innovations in life science applications

R&D 100 Awards 2024

Three awards for innovations in bioproduction and small-molecule analysis

R&D 100 Awards 2023

Received for 11 consecutive years (as of 2022)

CRO Leadership Awards

Received for 11 consecutive years (as of 2024)

CDMO Leadership Awards

Gold award for the Thermo Scientific Orbitrap Astral Mass Spectrometer in the R&D 100 Awards

Market Disruptor Special Recognition

Partnership with academic institutions for exosome research

Joint efforts in vaccine development and industrial process automation

Collaborations in vaccine research and industrial automation

Collaboration to automate order distribution using AI and ML technologies, reducing processing time from four days to 15 minutes

AI and ML-driven order distribution automation

Ongoing development of advanced DNA sequencing platforms

Developing next-generation sequencing technologies

Enhancing automation capabilities in various diagnostic processes

Automation in diagnostic testing

Development of a groundbreaking mass spectrometry instrument

Thermo Scientific Orbitrap Astral Mass Spectrometer

Creation of a high-sensitivity, high-throughput mass spectrometer for translational omics research

Thermo Scientific Stellar mass spectrometer

Innovative platform for cell therapy applications

Gibco CTS Detachable Dynabeads platform

Development of a novel single-use centrifuge system

DynaSpin Single-use Centrifuge

Creation of an advanced cell separation system for therapeutic applications

CTS DynaCellect Magnetic Separation System

Development of sustainable packaging like paper coolers for temperature-sensitive products

Eco-friendly packaging technologies

Thermo Fisher Scientific, an American multinational corporation, focuses on R&D in genomics, proteomics, and precision medicine. Its research spans life sciences, analytical instruments, specialty diagnostics, and laboratory products. Thermo Fisher develops next-generation sequencing technologies, advanced mass spectrometry instruments, and automation solutions for diagnostic testing and cell therapy applications. Its R&D efforts advance translational omics, biobanking, and sustainable laboratory practices.

A research lab focused on developing advanced mass spectrometry instruments and workflows for high-throughput proteomics and protein analysis.

Thermo Fisher Scientific

Overview

Featured Content

Thermo Fisher Scientific Center for Multiplexed Proteomics

Research Areas

R&D 100 Awards

Publications per Year

Patents per Year

Location on Map

Related Content

Thermo Fisher Scientific sets 2030 renewable goal with solar developer ib vogt

Explore More Labs